Who Paid My Doc
Andrea Medina Gonzalez
Dermatology Dorado, PR Medical Doctor
NPI 1346894664 CMS profile 11889192
D80 Calle C, Dorado, PR 00646
General payments
$1,332
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Andrea Medina Gonzalez of Dorado, PR is reported in the CMS Open Payments database as having received $1,332 across 24 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 39th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,332 | 24 |
Beside peers
- Andrea Medina Gonzalez
- Dermatology median
- Middle half of Dermatology
- National median
In program year 2025, general payments to Andrea Medina Gonzalez were reported at $1,332. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.
Show as a table
| Year | Andrea Medina Gonzalez | Dermatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $454 | $129–$1,240 | $163 |
| 2020 | $0 | $235 | $81–$756 | $114 |
| 2021 | $0 | $377 | $108–$1,108 | $132 |
| 2022 | $0 | $514 | $143–$1,391 | $149 |
| 2023 | $0 | $607 | $159–$1,674 | $160 |
| 2024 | $0 | $751 | $204–$1,903 | $164 |
| 2025 | $1,332 | $788 | $207–$1,974 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
274
Drug cost
$51,676
Branded share of claims
4.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dupixent Syringe Dupilumab | Brand | 12 | $44,829 | |
| Clobetasol Propionate | Generic | 48 | $2,006 | |
| Tacrolimus | Generic | 12 | $1,573 | |
| Triamcinolone Acetonide | Generic | 56 | $965 | |
| Ketoconazole | Generic | 65 | $852 | |
| Metronidazole | Generic | 17 | $720 | |
| Doxycycline Hyclate | Generic | 44 | $533 | |
| Terbinafine Hcl | Generic | 20 | $196 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.
Records
24 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Dermatology in Puerto Rico
Related records
Dermatology in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Dermatology
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.